DelveInsight’s “Nephrotic Syndrome Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Nephrotic Syndrome pipeline landscape. It covers the Nephrotic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nephrotic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Nephrotic Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/nephrotic-syndrome-pipeline-insight

Key Takeaways from the Nephrotic Syndrome Pipeline Report

• On June 08, 2026- Sanofi initiated a phase 2a study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.
• On May 29, 2026- Everest Medicines (China) Co. Ltd initiated a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at ~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.
• On May 12, 2026- Travere Therapeutics Inc. conducted a phase 2 study will evaluate long-term safety, tolerability, and efficacy with pharmacokinetic (PK) evaluations at Day 1 (Baseline), Day 2 (Visit 4), and Week 12 (Visit 9) in Population 1 and Population 2. In Population 3, PK values will be evaluated at Day 1 (Baseline) and at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96. For Population 1 and Population 2, subjects will be enrolled in 3 cohorts based on age ranges. For Population 3, subjects will be enrolled in one cohort.
• DelveInsight’s Nephrotic Syndrome Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Nephrotic Syndrome treatment.
• The leading Nephrotic Syndrome Companies such as GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB and others.
• Promising Nephrotic Syndrome Therapies such as Tacrolimus, ACTH, Mycophenolate Mofetil, Prednisone, Acid Mycophenolic, Mizoribine (MZR) and others.

Want to know which companies are leading innovation in Nephrotic Syndrome? @ Nephrotic Syndrome Clinical Trials Assessment

The Nephrotic Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Nephrotic Syndrome Pipeline Report also highlights the unmet needs with respect to the Nephrotic Syndrome.

Nephrotic Syndrome Overview

Nephrotic Syndrome is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling. Anyone can get Nephrotic Syndrome but it is slightly more common in men than in women. In children, it happens most often between the ages of 2 and 6.

Nephrotic Syndrome Emerging Drugs Profile

• Belimumab: GlaxoSmithKline

Belimumab is a fully human monoclonal antibody that has been developed by GlaxoSmithKline/MedImmune. Currently, it is in Phase II stage of clinical trial evaluation to treat Nephrotic Syndrome.

If you’re tracking ongoing Nephrotic Syndrome Clinical trials, this press release is a must-read @ Nephrotic Syndrome Treatment Drugs

Nephrotic Syndrome Companies

GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB and others.

The Nephrotic Syndrome Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Nephrotic Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nephrotic Syndrome Treatment.
• Nephrotic Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nephrotic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nephrotic Syndrome market.

Nephrotic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Nephrotic Syndrome Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

From emerging drug candidates to competitive intelligence, the Nephrotic Syndrome Pipeline Report covers it all @ Nephrotic Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Nephrotic Syndrome Pipeline Report

• Coverage- Global
• Nephrotic Syndrome Companies- GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB and others.
• Nephrotic Syndrome Therapies- Tacrolimus, ACTH, Mycophenolate Mofetil, Prednisone, Acid Mycophenolic, Mizoribine (MZR) and others.
• Nephrotic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nephrotic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Nephrotic Syndrome Treatment landscape in this detailed analysis @ Nephrotic Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Nephrotic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nephrotic Syndrome – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Belimumab: GlaxoSmithKline
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Nephrotic Syndrome Key Companies
15. Nephrotic Syndrome Key Products
16. Nephrotic Syndrome- Unmet Needs
17. Nephrotic Syndrome- Market Drivers and Barriers
18. Nephrotic Syndrome- Future Perspectives and Conclusion
19. Nephrotic Syndrome Analyst Views
20. Nephrotic Syndrome Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight